With many companies finding the costs of a closed R&D model unsustainable, a development construct that includes some sort of collaboration is necessary for long-term success. Or maybe you have an embarrassment of riches and your company’s platform or R&D efforts yielded more development candidates than you can take forward alone. The value of research collaborations, M&A and innovation centers are understood, but these only scratch the surface of unique methods to outsource or collaboratively further R&D.
From virtual R&D to open source to out licensing of “shelved” assets, this panel will explore the innovative business models offered to drug developers to bring capability and capital to create value and increase the realized value of research productivity.

Ability Level: All

Session ID: 21269